Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1390 with radiotherapy in recurrent glioblastoma
jRCT2051240119Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of azd1390 in glioblastoma (GBM), sponsored by AstraZeneca. Primary endpoints: Incidence of dose-limiting toxicities and Incidence of adverse events and serious adverse events. Started Sep 2024; status: active, not recruiting.
02
Drugs
azd1390
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2051240119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240119.